Thalidomide is a prescription medication with two FDA-approved uses: treating newly diagnosed multiple myeloma (a blood cancer) in combination with dexamethasone, and managing a painful skin complication of leprosy called erythema nodosum leprosum. It also has a well-known history as the drug that caused severe birth defects in more than 10,000 children in the late 1950s and early 1960s, which is why it’s now dispensed under one of the strictest safety programs in medicine.
Multiple Myeloma Treatment
Multiple myeloma is a cancer of plasma cells, a type of white blood cell found in bone marrow. Thalidomide is approved for newly diagnosed patients and is always given alongside a steroid called dexamethasone. The typical dose is 200 mg once daily, taken in 28-day cycles.
Thalidomide works against myeloma through several mechanisms. It suppresses the growth of new blood vessels that tumors need to survive, a process called angiogenesis. It does this by reducing the activity of key growth signals, particularly those that stimulate blood vessel formation. Thalidomide also dials down inflammation by lowering levels of tumor necrosis factor alpha (TNF-alpha), a protein the immune system produces that can fuel cancer growth. Together, these effects starve the tumor of its blood supply while disrupting the inflammatory environment it thrives in.
Leprosy Skin Reactions
Erythema nodosum leprosum (ENL) is a painful inflammatory reaction that affects some people with leprosy. It causes tender red nodules on the skin, often accompanied by fever, joint pain, and swelling. ENL isn’t the leprosy infection itself but an immune response that can flare up during or after treatment.
Thalidomide is approved both for acute flare-ups of moderate to severe ENL and as ongoing maintenance therapy to prevent recurrences. The starting dose ranges from 100 to 300 mg daily, adjusted based on severity. One important limitation: thalidomide alone isn’t recommended when ENL occurs alongside moderate to severe nerve inflammation, because it doesn’t adequately protect the nerves in that situation. The World Health Organization, notably, does not support thalidomide for ENL management due to its teratogenic risks, particularly in countries where access to reliable contraception and pregnancy monitoring may be limited.
Off-Label Uses
Doctors sometimes prescribe thalidomide for conditions beyond its two approved indications, based on its anti-inflammatory and immune-modulating properties. One area of interest is Crohn’s disease, a chronic inflammatory bowel condition. In a pilot study of 12 patients with steroid-dependent Crohn’s disease, low-dose thalidomide (50 to 100 mg nightly) produced clinical improvement in all patients during the first four weeks. By week 12, 70% had responded to treatment, and every patient was able to cut their steroid dose by at least half. Nearly half stopped steroids entirely. These results are preliminary, from a small, uncontrolled study, but they illustrate why thalidomide continues to attract clinical interest for inflammatory conditions that resist standard treatments.
The Birth Defects Crisis
Thalidomide was originally sold in the late 1950s across Europe, Australia, and parts of South America as a sedative and treatment for morning sickness during pregnancy. It was never approved in the United States, largely because an FDA reviewer named Frances Kelsey insisted on more safety data before clearing it. Her caution proved justified. The drug caused severe limb deformities and other birth defects in more than 10,000 children worldwide, along with an unknown number of miscarriages. The disaster reshaped drug regulation globally and remains one of the defining cautionary events in pharmaceutical history.
In 2018, researchers at Dana-Farber Cancer Institute finally uncovered the molecular mechanism behind those birth defects. Thalidomide binds to a protein called cereblon, which is part of the cell’s protein-recycling machinery. When thalidomide attaches to cereblon, it causes the destruction of proteins essential for limb development in a growing fetus. This discovery, six decades after the tragedy, also helped explain why thalidomide is effective against cancer: it hijacks the same recycling system to destroy proteins that myeloma cells need to survive.
How It’s Prescribed: The REMS Program
Because of its history, thalidomide is available in the U.S. only through a tightly controlled distribution program called the Risk Evaluation and Mitigation Strategy (REMS), originally known as S.T.E.P.S. (System for Thalidomide Education and Prescribing Safety). Only registered prescribers can write thalidomide prescriptions, and only registered pharmacies can fill them. Every prescription must be activated through a phone call to obtain a confirmation number before the pharmacy can dispense the medication, and no more than a 28-day supply can be given at once. Telephone prescriptions are not permitted.
The requirements for women of childbearing potential are especially rigorous. You must use two forms of birth control simultaneously, one highly effective method (such as an IUD, hormonal contraception, or tubal ligation) plus one barrier method (such as a condom or diaphragm). This regimen begins four weeks before starting thalidomide and continues for four weeks after stopping it. A pregnancy test with a negative result is required within 24 hours before the first dose. After that, pregnancy testing continues weekly for the first month, then every four weeks for women with regular cycles or every two weeks for those with irregular cycles.
Men taking thalidomide must use a latex condom during any sexual contact with women of childbearing potential, because the drug is present in semen. This applies even after a vasectomy.
Side Effects to Know About
Peripheral neuropathy, a type of nerve damage that typically causes tingling, numbness, or pain in the hands and feet, is the most significant side effect limiting thalidomide’s long-term use. In a prospective study of 135 patients, about 25% developed clear clinical and electrical signs of nerve damage. When researchers included subtler cases detectable only through nerve conduction testing, the rate reached nearly 56%. The risk is highest during the first year of treatment, when roughly 20% of patients develop neuropathy. About a quarter of affected patients had no symptoms at all, meaning nerve damage was already occurring silently.
Other common side effects include drowsiness (thalidomide was, after all, originally a sedative), swelling, constipation, and skin rashes. Blood clots are a recognized risk, particularly when thalidomide is combined with dexamethasone for myeloma treatment. Your doctor will typically prescribe blood-thinning medication alongside thalidomide to reduce this risk.